[go: up one dir, main page]

RU2018130986A - Антитела к jagged и способы их применения - Google Patents

Антитела к jagged и способы их применения Download PDF

Info

Publication number
RU2018130986A
RU2018130986A RU2018130986A RU2018130986A RU2018130986A RU 2018130986 A RU2018130986 A RU 2018130986A RU 2018130986 A RU2018130986 A RU 2018130986A RU 2018130986 A RU2018130986 A RU 2018130986A RU 2018130986 A RU2018130986 A RU 2018130986A
Authority
RU
Russia
Prior art keywords
jagged
antibodies
ways
application
hvr
Prior art date
Application number
RU2018130986A
Other languages
English (en)
Other versions
RU2018130986A3 (ru
Inventor
Кристиан В. СИБЕЛ
Янь Ву
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2018130986A publication Critical patent/RU2018130986A/ru
Publication of RU2018130986A3 publication Critical patent/RU2018130986A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

  1. Выделенное антитело, которое связывается с Jagged2, содержащее по меньшей мере одну, две, три, четыре, пять или шесть HVR, выбранных из:
  2. (a) HVR-H1, содержащей аминокислотную последовательность SEQ ID NO: 88;
  3. (b) HVR-H2, содержащей аминокислотную последовательность SEQ ID NO: 89;
  4. (c) HVR-H3, содержащей аминокислотную последовательность SEQ ID NO: 94;
  5. (d) HVR-L1, содержащей аминокислотную последовательность SEQ ID NO: 115;
  6. (e) HVR-L2, содержащей аминокислотную последовательность SEQ ID NO: 116; и
  7. (f) HVR-L3, содержащей аминокислотную последовательность SEQ ID NO: 122.
RU2018130986A 2012-08-13 2013-08-13 Антитела к jagged и способы их применения RU2018130986A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261682640P 2012-08-13 2012-08-13
US61/682,640 2012-08-13
US201361784332P 2013-03-14 2013-03-14
US61/784,332 2013-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015108797A Division RU2666990C2 (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения

Publications (2)

Publication Number Publication Date
RU2018130986A true RU2018130986A (ru) 2018-10-09
RU2018130986A3 RU2018130986A3 (ru) 2021-12-22

Family

ID=49004047

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018130986A RU2018130986A (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения
RU2015108797A RU2666990C2 (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015108797A RU2666990C2 (ru) 2012-08-13 2013-08-13 Антитела к jagged и способы их применения

Country Status (10)

Country Link
US (4) US10113002B2 (ru)
EP (1) EP2882776B1 (ru)
JP (4) JP6352264B2 (ru)
KR (2) KR102193080B1 (ru)
CN (1) CN104520328B (ru)
BR (1) BR112015003032B1 (ru)
CA (1) CA2880271C (ru)
MX (2) MX381841B (ru)
RU (2) RU2018130986A (ru)
WO (1) WO2014028446A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
EP2863948B1 (en) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
RU2018130986A (ru) 2012-08-13 2018-10-09 Дженентек, Инк. Антитела к jagged и способы их применения
US10350216B2 (en) * 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
KR20150128707A (ko) 2013-03-15 2015-11-18 제넨테크, 인크. 간암의 진단 및 치료를 위한 조성물 및 방법
WO2015123325A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030170636A1 (en) 2002-03-05 2003-09-11 Isis Pharmaceuticals Inc. Antisense modulation of jagged 2 expression
US20030185829A1 (en) 2002-03-12 2003-10-02 Erich Koller Jagged 2 inhibitors for inducing apoptosis
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
AU2003259381A1 (en) 2002-08-29 2004-03-19 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
DK1578397T3 (da) 2002-11-15 2013-03-11 Genmab As Humane monoklonale antistoffer mod CD25
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2546017A1 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
KR20160096228A (ko) 2004-07-22 2016-08-12 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
WO2008076960A2 (en) 2006-12-18 2008-06-26 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2125896A2 (en) 2007-02-09 2009-12-02 Genetech, Inc. Anti-robo4 antibodies and uses therefor
US8802103B2 (en) 2007-05-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
JP2009078998A (ja) 2007-09-26 2009-04-16 Univ Of Tokushima Ｊａｇｇｅｄ２を用いる制癌剤
CA2720763A1 (en) * 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
AU2009298569A1 (en) 2008-10-01 2010-04-08 Genentech, Inc. Anti-Notch2 antibodies and methods of use
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
US8945569B2 (en) * 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
EP2863948B1 (en) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
RU2018130986A (ru) 2012-08-13 2018-10-09 Дженентек, Инк. Антитела к jagged и способы их применения
KR20150128707A (ko) 2013-03-15 2015-11-18 제넨테크, 인크. 간암의 진단 및 치료를 위한 조성물 및 방법
WO2015123325A1 (en) 2014-02-12 2015-08-20 Genentech, Inc. Anti-jagged1 antibodies and methods of use
BR112017000130A2 (pt) * 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer

Also Published As

Publication number Publication date
BR112015003032A2 (pt) 2017-12-12
WO2014028446A1 (en) 2014-02-20
US20190135936A1 (en) 2019-05-09
EP2882776A1 (en) 2015-06-17
JP2020048563A (ja) 2020-04-02
BR112015003032B1 (pt) 2023-03-28
MX2015001942A (es) 2015-08-14
MX381841B (es) 2025-03-13
CN104520328B (zh) 2019-06-07
BR112015003032A8 (pt) 2018-04-10
CA2880271C (en) 2021-10-19
EP2882776B1 (en) 2018-05-02
JP6619047B2 (ja) 2019-12-11
US11702479B2 (en) 2023-07-18
US10113002B2 (en) 2018-10-30
RU2015108797A (ru) 2016-10-10
CN104520328A (zh) 2015-04-15
KR102193080B1 (ko) 2020-12-18
CA2880271A1 (en) 2014-02-20
RU2666990C2 (ru) 2018-09-13
MX357675B (es) 2018-07-18
KR20200143502A (ko) 2020-12-23
RU2018130986A3 (ru) 2021-12-22
JP2021191275A (ja) 2021-12-16
HK1209432A1 (en) 2016-04-01
JP2015530989A (ja) 2015-10-29
JP7366700B2 (ja) 2023-10-23
KR20150041656A (ko) 2015-04-16
US10689455B2 (en) 2020-06-23
JP6352264B2 (ja) 2018-07-04
US20240034805A1 (en) 2024-02-01
JP2018139595A (ja) 2018-09-13
US20200377610A1 (en) 2020-12-03
US20150232568A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
RU2018130986A (ru) Антитела к jagged и способы их применения
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
RU2019125027A (ru) Афукозилированные антитела к рецептору фактора роста фибробластов fgfr2iiib
JP2016063812A5 (ru)
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2020500538A5 (ru)
NZ626520A (en) Anti-lrp5 antibodies and methods of use
JP2012116856A5 (ru)
WO2013003680A8 (en) Anti-c-met antibody formulations
EP4252769A3 (en) Anti-complement factor c1q antibodies and uses thereof
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
JP2016503413A5 (ru)
PE20181402A1 (es) Anticuerpos anti-c5 y metodos de uso
PE20180317A1 (es) Anticuerpos anti-tau y metodos de uso
RU2011134500A (ru) Антитела и иммуноконъюгаты и их применения
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
NZ602040A (en) Anti-lrp6 antibodies
AR096364A1 (es) Anticuerpos receptores de antitransferina y métodos de uso
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS